Clearside Biomedical Inc reports results for the quarter ended December 31 - Earnings Summary

Clearside Biomedical,

27/03/2025 21:02

Clearside Biomedical Inc CLSD.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -8 cents.  The mean expectation of seven analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -13 cents to -4 cents per share.

Revenue fell 95.2% to $306.00 thousand from a year ago; analysts expected $176.67 thousand.

Clearside Biomedical Inc's reported EPS for the quarter was a loss of 10 cents​.

The company reported a quarterly loss of $7.31 million.

Clearside Biomedical Inc shares had risen by 7.4% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Clearside Biomedical Inc is $6.00

This summary was machine generated from LSEG data March 27 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.10
-0.10
Met
Sep. 30 2024
-0.12
-0.10
Beat
Jun. 30 2024
-0.13
-0.10
Beat
Mar. 31 2024
-0.14
-0.15
Missed